<DOC>
	<DOCNO>NCT02971345</DOCNO>
	<brief_summary>It prospective multi-center clinical research China compare efficacy , safety related impact factor TACE alone endovascular brachytherapy combine stent placement TACE HCC main portal vein tumor thrombus .</brief_summary>
	<brief_title>Endovascular Brachytherapy Combined With Stent Placement TACE HCC With Main Portal Vein Tumor Thrombus</brief_title>
	<detailed_description>It open random prospective phase III clinical trial conduct Principal Investigator Professor Zhi-ping Yan.Investigators twenty-seven hospital China participate in.Patients unresectable HCC main portal vein tumor thrombus enrol . The investigator propose recruitment 253 patient randomly assign combined group ( treat endovascular brachytherapy combined stent placement TACE ) control group ( treated TACE alone ) .There 127 patient combine group 126 patient control group . The criterion inclusion exclusion , method lab test , image modality treatment procedure .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<criteria>( 1 ) Hepatocellular carcinoma ( HCC ) diagnosis confirm needle biopsy two coincidental image technique associate increase αfetoprotein accord American Association Study Liver Diseases ( AASLD ) guideline ; ( 2 ) According Barcelona Clinic Liver Cancer stag classification , HCC unsuitable resection , liver transplantation percutaneous radiofrequency ablation ; ( 3 ) Tumor thrombus , lowattenuation intraluminal filling defect extend intrahepatic portal vein branch adjacent primary tumor main portal vein , confirm contrastenhanced abdominal computer tomography ( CT ) magnetic resonance imaging ( MRI ) ( 4 ) At least firstorder branch intrahepatic portal vein patent one lobe ; ( 5 ) ChildPugh classification grade A B ; ( 6 ) Eastern Cooperative Oncology Group ( ECOG ) performance status score 2 less ; ( 1 ) Patients history therapy HCC portal vein tumor thrombus ; ( 2 ) Advanced liver disease ( bilirubin level &gt; 3 mg/dL , Aspartate transaminase Alanine aminotransferase &gt; 5 × upper limit normal ) ； ( 3 ) Tumor invade Inferior Vena Cava , extrahepatic spread ; ( 4 ) Any contraindication arterial procedure impair clot test ( platelet count 50 × 109/L prothrombin activity 50 % ) ; ( 5 ) Renal failure , cardiac ejection fraction ( &lt; 50 % ) endstage disease ; ( 6 ) Patients capable cooperation procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>main portal vein tumor thrombus</keyword>
	<keyword>endovascular brachytherapy</keyword>
	<keyword>stent</keyword>
	<keyword>chemoembolization</keyword>
</DOC>